
浏览全部资源
扫码关注微信
1. 重庆医科大学临床学院心内科
2. 重庆医科大学临床学院心内科,重庆,400016
纸质出版日期:2005,
扫 描 看 全 文
[1]李骊华,邓国兰,陈运贞.临床常用剂量下的舒降之、血脂康、美百乐镇对原发性高脂血症调脂作用的比较[J].重庆医科大学学报,2005(02):278-281+284.
LI Lihua, et al. Clinical comparative study of simvastatin, xuezhikang and pravastatin in common doses on primary hyperlipidemia[J]. Journal of Chongqing Medical University, 2005,(2):278-281.
[1]李骊华,邓国兰,陈运贞.临床常用剂量下的舒降之、血脂康、美百乐镇对原发性高脂血症调脂作用的比较[J].重庆医科大学学报,2005(02):278-281+284. DOI: 10.13406/j.cnki.cyxb.2005.02.033.
LI Lihua, et al. Clinical comparative study of simvastatin, xuezhikang and pravastatin in common doses on primary hyperlipidemia[J]. Journal of Chongqing Medical University, 2005,(2):278-281. DOI: 10.13406/j.cnki.cyxb.2005.02.033.
目的:验证舒降之、血脂康、美百乐镇的调脂作用并做比较研究。方法:6 0例高脂血症患者随机分为3组
舒降之2 0mg每晚顿服;美百乐镇10mg每晚顿服;血脂康0 .6 g早晚各1次口服;服药前及服药后4、8、12周测定血脂。结果:舒降之组治疗后4周TC、LDL -C有下降(P <0 .0 5 )
12周比4周下降更明显(P <0 .0 5 )。美百乐镇组治疗后4周TC、LDL -C有下降(P <0 .0 5 )
12周与4周无明显变化(P >0 .0 5 )。两组的TG、HDL -C治疗前后均无明显变化(P >0 .0 5 )。血脂康组治疗后4周TC、LDL -C、TG有下降(P <0 .0 5 )
TC、LDL -C 12周比4周下降更明显(P <0 .0 5 ) ;HDL治疗前后无明显变化(P>0 .0 5 )。舒降之组治疗后8周、12周LDL -C分别下降( 4 0 %
4 5 % )
明显大于血脂康组( 31%与36 % )和美百乐镇组( 31%与35 % ) (P <0 .0 5 )。血脂康组治疗后8周、12周TG分别下降( 33%
35 % )
明显大于舒降之组( 2 5 %
2 6 % )和美百乐镇组( 18%
19% ) (P <0 .0 5 )。3组TC、TG、HDL -C总有效率无显著差异(P >0 .0 5 )。结论:舒降之、血脂康、美百乐镇降脂疗效确切
但3种药疗效判断及调整治疗的时间窗不同。舒降之降LDL -C能力强
血脂康降TG能力强且较经济实用
Objective:To compare the effects of simvastatin
xuezhikang and pravastatin in patients with primary hyperlipidemia.Methods:Sixty patients were randomly divided into three groups
simvastatin 20mg were taken once a day at night;provastatin 10mg were taken once a day at night;xuezhikang 0.6g were taken twice a day in the morning and at night.Blood samples were taken before and 4 weeks
8 weeks
12 weeks after the treatment.Results:In simvastatin group:the serum levels of total cholesterol(TC)
low-density lipoprotein cholesterol(LDL C) decreased markedly at the end of 4 weeks compared with those of the baseline ( P <0.05).Significant differences in TC
LDL C were found between the end of 4 weeks and 12 weeks ( P <0.05).In pravastatin group:there is a noticeable drop in TC
LDL C at the end of 4 weeks
but no further obvious drop between 4 weeks and 12 weeks.Concentrations of TG and HDL C were not changed obviously in both groups after 12 weeks of treatment compared with the baseline ( P >0.05).In xuezhikang group:after 4 weeks of treatment
TC
TG
LDL C reduced markedly( P <0.05).Further significant lowering of TC
LDL C were noted after 12 weeks as compared with 4 weeks ( P <0.05).Only HDL C was not changed after the treatment in contrast with the baseline ( P >0.05).From the change rates
we can see after 8 weeks
12 weeks of treatment the level of LDL C drcreased more significantly in simvastatin group (40%
45%) than in xuezhikang (31%
36%) and provastatin (31%
35%) ( P <0.05);however
the level of TG lowered more obviously in xuezhikang group (33%
35%) than in simvastatin(25%
26%) and provastatin (18%
19%)( P <0.05).At the end of 12 weeks
the total effective rates of decreasing TC
TG
HDL C have no significance among three groups ( P >0.05).Conclusion:The clinical effects of simvastatin
xunzhikang
provastatin on primary hyperlipidemia were equal among the three groups
but the time is different about when they take great effects respectively.Next
LDL C lowering effect of simvastatin was significant.Finally
xuezhikang was the best in reducing TG among the three groups and it has a relatively good economic effectiveness.
高脂血症舒降之血脂康美百乐镇
hyperlipidemiaSimvastatinXuezhikangProvastatin
0
浏览量
115
下载量
6
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621